General Info
| Host: | E. coli |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: | 2019-nCoV Envelope-N-His&Avi protein was developed from e. coli and has a target region of N-His&Avi. For use in research applications. |
| Formulation: | Supplied as a 0.22 Mu m filtered solution in 20mM TRIS, 250mM NaCl, 0.5%TritonX-100, pH 8.0. Contact us for customized product form or formulation. |
| Immunoreactivity: | Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Envelope at 2 Mu g/mL (100 Mu L/well) can bind Recombinant SARS-CoV-2 Nucleocapsid with a linear range of 1.2-41.1 ng/mL. |
Information
| Immunogen Region: | Met1-Val75 |
| Immunogen: | Recombinant SARS-CoV-2 (2019-nCoV) Envelope Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Val75) of SARS-COV-2 (2019-nCoV) Envelope (Accession #QHD43418.1) fused with an initial Met, a 6×His, Av |
Description
| Background | Recombinant SARS-CoV-2 (2019-nCoV) Envelope Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Val75) of SARS-COV-2 (2019-nCoV) Envelope (Accession #QHD43418.1) fused with an initial Met, a 6×His, Avi tag at the N-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance